Breast Cancer Clinical Trial
Official title:
Phase II, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Primary:
- To assess the safety and tolerability and to find the maximum tolerated dose of the
combination administration of RAD001 plus docetaxel when given to patients with
metastatic breast cancer who are being considered for standard docetaxel treatment
(phase I).
- To characterize the pharmacokinetics of RAD001 and docetaxel when co-administered
(phase I).
Secondary:
- To assess the clinical efficacy of the combination regimens in this patient population
as shown by response (according to the modified RECIST criteria) (phase II).
- To determine the phosphorylation status of the components of the mTOR signaling pathway
and the expression of modifiers of apoptosis in the primary breast tumors, in order to
determine whether these markers can be used as predictors of sensitivity to the
combination of RAD001 and docetaxel
- To determine the effect of the combination of RAD001 and docetaxel on the expression
and phosphorylation of mTOR's targets in the accessible tumor tissue, in order to
identify potential pharmacodynamics markers of response to this drug combination
Docetaxel is a drug approved for the treatment of metastatic breast cancer in patients who
are either newly diagnosed or have failed earlier chemotherapy. RAD001 is an investigational
drug that has shown to have anticancer properties. It also works by weakening the immune
system. RAD001 works by blocking some of the steps required for cancer growth. The
researcher hopes that RAD001 may increase the anticancer activity of docetaxel.
If you are found to be eligible to take part in this study, you will receive docetaxel by
vein on Day 1 over one hour. RAD001 will be given by mouth on Days 1 and 8. RAD 001 will be
given on an empty stomach or after a light meal. You will repeat this treatment every 21
days. Three (3 ) weeks equals 1 cycle.
Patients who participated on the first phase of study numbered 2004-0758 will be eligible
for the study. The study will done using the highest dose of RAD001 and docetaxel that was
found to be safe and effective during the first phase of the study.
Dexamethasone will be given by mouth twice a day for 3 days, starting the day before you
receive docetaxel. Dexamethasone helps decrease the risk of and control nausea, vomiting,
and fluid retention.
Blood (between 1-2 teaspoons) will be drawn for routine tests at each visit. X-rays and
scans (CT or MRI) will be done every 6 weeks to see if the tumor is responding to treatment.
After 6 cycles of the combination, docetaxel will be stopped and you will continue to take
RAD001 alone. However, you may be able to take more than 6 cycles of the combination if you
are not having any side effects and is found to be of benefit by your primary doctor.
Once you go off treatment, you will have a physical exam, including routine blood tests (1-2
teaspoons).
This is an investigational study. Docetaxel is approved by the FDA and commercially
available for the treatment of breast cancer. RAD001 is authorized for use in research only.
About 65 patients will take part in the study. All will be enrolled at M. D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |